


Elubrixin tosylate

Cat. No.:	HY-18263C
CAS No.:	960495-43-6
Molecular Formula:	C ₂₄ H ₂₅ Cl ₂ FN ₄ O ₇ S ₂
Molecular Weight:	635.51
Target:	CXCR; Interleukin Related
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (196.69 mM; Need ultrasonic and warming)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.5735 mL	7.8677 mL	15.7354 mL
		5 mM		0.3147 mL	1.5735 mL	3.1471 mL
10 mM		0.1574 mL	0.7868 mL	1.5735 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.27 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.27 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.27 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC ₅₀ of 260.7 nM) and shape change (IC ₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation ^{[1][2][3]} .	
IC₅₀ & Target	CXCR2	IL-8
In Vitro	Elubrixin has an inhibitory effect on neutrophils in a dose-dependent fashion ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

- [1]. Mozaffari S, et al. Inflammatory bowel disease therapies discontinued between 2009 and 2014. *Expert Opin Investig Drugs*. 2015;24(7):949-56.
- [2]. Lazaar AL, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. *Br J Clin Pharmacol*. 2011 Aug;72(2):282-93.
- [3]. Nicholson GC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. *Pulm Pharmacol Ther*. 2007;20(1):52-9.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA